

REFERENCES

1. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. *Science*. 1996; 271: 518-20.
2. Ammon HPT, Wahl MA. Pharmacology of Curcuma longa. *Planta Med*. 1991; 57: 1-7.
3. Anuchapreeda S, Muangmoonchai R, Limtrakul P. Effect of curcuminoids on MDR1 gene promoter activity in human cervical carcinoma cells. *Chiang Mai Med Bull*. 2002; 41: 35-43.
4. Arun N, Nalini N. Efficacy of turmeric on blood sugar and polyol pathway in diabetic albino rats. *Plant Foods in Human Nutrition*. 2002; 57: 41-52.
5. Aviram M, Lund-Katz S, Phillips MC, Chait A. The influence of the triglyceride content of low density lipoprotein on the interaction of apolipoprotein B-100 with cells. *J Biol Chem*. 1988; 263: 16842-5.
6. Baillie G, Owens MD, Halbert GW. A synthetic low density lipoprotein particle capable of supporting U937 proliferation in vitro. *J Lipid Res*. 2002; 43: 69-73.
7. Beisiegel U. Receptors for triglyceride-rich lipoproteins and their role in lipoprotein metabolism. *Curr Opin Lipidol*. 1995; 6: 117-22.
8. Belcher JD, Balla J, Balla G. Vitamin E, LDL, and endothelium: brief oral vitamin supplementation prevents oxidized LDL-mediated vascular injury in vitro. *Arterioscler Thromb*. 1993; 13: 1779-89.
9. Berliner JA, Heinecke JW. The role of oxidized lipoproteins in atherogenesis. *Free Radic Biol Med*. 1996; 20: 720-7.
10. Berliner JA, Territo MC, Sevanian A. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. *J Clin Chem*. 1990; 85: 1200-30.
11. Billheimer JT, Chamoun D, Esfahani M. Defective 3-ketosteroid reductase activity in a human monocyte-like cell line. *J Lipid Res*. 1987; 28: 704-9.
12. Bowie A, Owens D, Collins P, Johnson A, Tomkin GH. Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patient?. *Atherosclerosis*. 1993; 102: 63-7.

13. Brewer HBJr, Gregg RE, Hoeg JM, Fojo SS. Apolipoproteins and lipoproteins in human plasma: an overview. *Clin Chem.* 1988; 34: B4-8.
14. Brown MS, Kovanen P, Goldstein J. Regulation of plasma cholesterol by lipoprotein receptors. *Science.* 1981; 212: 628-35.
15. Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants *in vivo* can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. *Proc Natl Acad Sci.* 1987; 84: 7725-9.
16. Carr AC, Zhu BZ, Frei B. Potential antiatherogenic mechanisms of ascorbate (vitamin C) and alpha-tocopherol (vitamin E). *Circ Res.* 2000; 87: 349-54.
17. Chapman MJ, Guerin M, Bruckert E. Atherosclerosis, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches. *Eur Heart J.* 1998; 19 Suppl A: A24-30.
18. Cheng X, Cui Y, Chen Y, Zhang X. Effects of alpha-tocopherol and beta-carotene on the oxidized low density lipoprotein induced by Cu^{2+} . *Circulation.* 1993; 88: 2780-6.
19. Chung BH, Wilkinson T, Geer JC, and Segrest JP. Preparative and quantitative isolation of plasma lipoproteins: rapid, single discontinuous density gradient ultracentrifugation in a vertical rotor. *J Lipid Res.* 1980; 21: 284-91.
20. Dahlen G, Berg K, and Frick MH. Lp(a) lipoprotein/pre- β -lipoprotein, serum lipids and atherosclerotic disease. *Clin Genet.* 1976; 9: 558-66.
21. Deckelbaum RJ. Structure and composition of plasma lipoproteins. In: Atherosclerosis. Biology and Clinical Science. *Churchill Livingstone.* New York. 1987; 32: 25-5.
22. Del Mastero RF. An approach to free radicals in medicine and biology. *Acta Physiol Scand.* 1980; 492: 153-68.
23. Diaz MN, Frei B, Vita JA, Keaney JF Jr. Antioxidants and atherosclerotic heart disease. *N Engl J Med.* 1997; 337: 408-16.
24. Eisenberg S. High density lipoprotein metabolism. *J Lipid Res.* 1984; 25: 1017-58.
25. Elaine JB, Wendy J, Keith KS, Roger TD. Loading with oxidised low density lipoprotein alters endocytic and secretory activities of murine macrophages. *Biochem Biophys Acta.* 1997; 1356: 12-22.

26. Ericson C, Dahlen G, and Ersson NO. Some comments on the Kohn staining technique of lipoproteins after electrophoresis on cellulose acetate. *Scand J Clin Lab Invest.* 1975; 35: 479-80.
27. Esterbauer H, Gebicki J, Puhl H, and Jürgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. *Free Radic Biol Med.* 1992; 13: 341-50.
28. Esterbauer H, Jungens G. Mechanistic and genetic aspects of susceptibility of LDL to oxidation. *Curr Opinion Lipidol.* 1993; 4: 114-24.
29. Esterbauer H, Ramos P. Chemistry and pathophysiology of oxidation of LDL. *Rev Physiol Biochem Pharmacol.* 1995; 127: 31-64.
30. Esterbauer H, Striegel G, Puhl H, Rotheneder M. Continuous monitoring of vitro oxidation of human low density lipoprotein. *Free Radical Res.* 1989; 6: 67-75.
31. Franceschini G, Moderna P, Sirtori CR. Reverse cholesterol transport: physiology and pharmacology. *Atherosclerosis.* 1991; 88: 99-107.
32. Frei B. On the role of vitamin C and other antioxidants in atherogenesis and vascular dysfunction. *Proc Soc Exp Biol Med.* 1999; 222: 196-204.
33. Frostegard J, Hamsten A, Gidlund M, Nilsson J. Low density lipoprotein-induced growth of U937 cells: a novel method to determine the receptor binding of low density lipoprotein. *J lipid Res.* 1990; 31: 37-44.
34. Frostegard J, Regnstrom J, Tornvall P, Hamsten A, Nilsson J. The susceptibility of low density lipoprotein to chemical oxidation is closely related to proneness to biological modification. *Free Radic Res.* 1995; 23: 581-92.
35. Ghatak N, Basu N. Sodium curcuminat as an effective anti-inflammatory agent. *Indian J Exptal Biol.* 1972; 10: 235-8.
36. Giese SP, Esterbauer H. Low density lipoprotein is saturable by prooxidant copper. *FEBS Lett.* 1994; 343: 188-94.
37. Ginsberg HN. Lipoprotein physiology and its relationship to atherogenesis. *Endocrinol Metab Clin North Am.* 1990; 19: 211-28.
38. Glueck CJ, Shaw P, Lang JE, *et al.* Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients. *Am J Cardiol.* 1995; 75: 132-6.

39. Gokce N, Frei B. Basic research in antioxidant inhibition of steps in atherogenesis. *J Cardiovasc Risk*. 1996; 3: 352-7.
40. Goldstein J, Brown M. The low density lipoproteins pathway and its relation to atherosclerosis. *Ann Rev Biochem*. 1977; 46: 897-906.
41. Goldstein JL, Brown MS. The metabolic basis of inherited disease. New York: *McGraw-Hill*. 1973; pp 672-713.
42. Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake of and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. *Proc Natl Acad Sci*. 1979; 76: 333-77.
43. Gotto AM Jr, Pownall HJ, Havel RJ. Introduction of the plasma lipoproteins. *Methods Enzymol*. 1986; 128: 3-41.
44. Greaves DR, Gough PJ, Gordon S. Recent progress in defining the role of scavenger receptors in lipid transport, atherosclerosis and host defence. *Curr Opin Lipidol*. 1998; 9: 425-32.
45. Gros M, Jurman-Gros T. Electrophoretical separation of pre-stained serum lipoproteins on cellulose acetate, agarose gel and polyacrylamide. *Clin Chim Acta*. 1973; 45: 165-7.
46. Grundy SM. Role of low-density lipoproteins in the atherogenesis and development of coronary heart disease. *Clin Chem*. 1995; 41: 139-46.
47. Guetta V, Cannon RO. Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women. *Circulation*. 1996; 93: 1928-37.
48. Gutteridge JM, Halliwell B. Antioxidants in Nutrition, Health, and Disease. New York: *Oxford University Press*. 1994; 111-23.
49. Han J, Hajjar DP, Febbraio M, and Nicholson AC. Native and Modified Low Density Lipoproteins Increase the Functional Expression of the Macrophage Class B Scavenger Receptor, CD36. *J Biol Chem*. 1997; 272: 21654-9.
50. Hass R, Bartels H, Topley N, Hadam M, Kohler L, Goppelt-Strube M and Resch K: TPA-induced differentiation and adhesion of U937 cells. Changes in ultrastructure, cytoskeletal organization and expression of cell surface antigens. *Eur J Cell Biol*. 1989; 48: 282-93.

51. Hayashi K, Dojo S, Hirata Y, et al. Metabolic changes in LDL receptors and an appearance of scavenger receptors after phorbol ester-induced differentiation of U937 cells. *J Lipid Res.* 1998; 43: 69-73.
52. Heather MK, Anna B, Michael JD, Roger TD. Comparative time-course of copper-ion-mediated protein and lipid oxidation in low density lipoprotein. *Arch Biochem Biophys.* 2002; 400: 223-32.
53. Heinecke JW. Oxidants and antioxidants in the pathogenesis of atherosclerosis: implication for the oxidized low density lipoprotein hypothesis. *Atherosclerosis.* 1998; 141: 1-15.
54. Hessler JR, Morel DW, Lewis LJ, Chisolm GM. Lipoprotein oxidation and lipoprotein-induced cytotoxicity. *Arterioscler.* 1983; 3: 215-22.
55. Himber J, Buhler E, Moll D, Moser UK. Low density lipoprotein for oxidation and metabolic studies. Isolation from plasma using a ultracentrifuge. *Int J Vitam Nutr Res.* 1995; 65: 137-42.
56. Jain SK, McVie R, Jaramillo JJ, et al. The effect of modest vitamin E supplementation on lipid peroxidation products and other cardiovascular risk factors in diabetic patients. *Lipids.* 1996; 31: 87-90.
57. Jessup W, Rankin SM, De Whalley CV, et al. Alpha-Tocopherol consumption during low-density lipoprotein oxidation. *Biochem J.* 1990; 265: 399-405.
58. Jha P, Flather M, Lonn E, Farkouh M, Yusuf S. The antioxidant vitamins and cardiovascular disease. A critical review of epidemiologic and clinical trial data. *Ann Intern Med.* 1995; 123: 860-72.
59. Jialal I, Grundy SM. Effect of combined supplementation with alpha-tocopherol, ascorbate, and beta carotene on low-density lipoprotein oxidation. *Circulation.* 1993;88(6):2780-6.
60. Jialal I, Grundy SM. Influence of antioxidant vitamins on LDL oxidation. *Ann N Y Acad Sci.* 1992; 669: 237-48.
61. Jones A, Hdadek C, Hornik G. Uptake and processing of remnants of chylomicrons and very low density lipoproteins by rat liver. *J Lipid Res.* 1984; 25: 1151-7.
62. Julier K, Mackness MI, Dean JD, Durrington PN. Susceptibility of low- and high-density lipoproteins from diabetic subjects to in vitro oxidative modification. *Diabet Med.* 1999; 16: 415-23.

63. Kehrer JP. Free radicals as mediators of tissue injury and disease. *Crit Rev Toxicol.* 1993; 23: 21-48.
64. Knott HM, Brown BE, Davies MJ, Dean RT. Glycation and glycooxidation of low-density lipoproteins by glucose and low-molecular mass aldehydes. *Eur J Biochem.* 2003; 270: 3572-82.
65. Koenig W. Inflammation and coronary heart disease: an overview. *Cardiol Rev.* 2001; 9: 31-5.
66. Kondo A, Muranaka Y, Ohta I, *et al.* Relationship between triglyceride concentrations and LDL size evaluated by malondialdehyde-modified LDL. *Clin Chem.* 2001; 47: 893-900.
67. Krieger M. The other side of scavenger receptors: pattern recognition for host defense. *Curr Opin Lipidol.* 1997; 8: 275-80.
68. Kuzuya M, Yamada K, Hayashi T, *et al.* Role of lipoprotein-copper complex in copper catalyzed-peroxidation of low density lipoprotein. *Biochim Biophys Acta.* 1992; 1123: 334-41.
69. Laker MF, Winocour PF: Plasma lipids and lipoproteins in diabetes mellitus. *Diabetes Annu.* 1991; 6: 431-56.
70. Lavy A, Brook GJ, Danker G, Amotz AB, Aviram M. Enhanced *in vitro* oxidation of plasma lipoproteins derived from hypercholesterolemic patients. *Metabolism.* 1991; 40: 794-99.
71. Liguori A, Abete P, Hayden JM, *et al.* Effect of glycaemic control and age on low-density lipoprotein susceptibility to oxidation in diabetes mellitus type 1. *Eur Heart J.* 2001; 22: 2075-84.
72. Limtrakul P, Lipigorngoson S, Namwong O, Apisariyakul A, Dunn FW. Inhibition of curcumin on tumour initiation and promotion stage in mouse skin tumorigenesis. *Cancer Lett.* 1997; 116: 197-203.
73. Losonczy KG, Harris TB, Havlik RJ. Vitamin E and vitamin C supplement use and risk of all-cause and coronary heart disease mortality in older persons: the Established Populations for Epidemiologic Studies of the Elderly. *Am J Clin Nutr.* 1996; 64: 190-6.
74. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. *J Biol Chem.* 1951; 193: 265-8.

75. Mahley RW. Biochemistry and physiology of lipid and lipoprotein metabolism. Philadelphia: JB Lippincott. 1990; 1219-29.
76. Maranhao RC. Lipoprotein (a) in subjects with or without coronary artery disease: relation to clinical history and risk factors. *Braz J Med Biol Res.* 1995; 28: 439-46.
77. Mazumder A, Raghavan K, Weinstein J, *et al.* Inhibition of human immunodeficiency virus type-1 integrase by curcumin. *Biochem Pharmacol.* 1995; 49: 1165-70.
78. Miller NJ, Rice-evans C, Davis MJ, Gopinahan V, and Milner A. A novel method for measuring antioxidant capacity and its application to vitamin E (α -tocopherol) in serum. *Clin Chem.* 1993; 10: 1078-86.
79. Mori M, Itabe H, Higashi Y. *et al.* Foam cell formation containing lipid droplets enriched with free cholesterol by hyperlipidemic serum. *J. Lipid Res.* 2001; 42: 1771-81.
80. Nagabhushan M, Bhide SV. Antimutagenicity and anticarcinogenicity of turmeric. *J Nutr Growth Canc.* 1987; 4: 83-5.
81. Naidu KA, Thippeswamy NB. Inhibition of human low density lipoprotein oxidation by active principles from spices. *Mol Cell Biochem.* 2002; 229: 19-23.
82. Nielsen LB. Atherogenicity of lipoprotein(a) and oxidized low density lipoprotein: insight from in vivo studies of arterial wall influx, degradation and efflux. *Atherosclerosis.* 1999; 143: 229-43.
83. Nyssönen K, Porkkala E, Salonen R, Korpela H, Salonen JT. Increase in oxidation resistance of atherogenic serum lipoproteins following antioxidant supplementation: a randomized double-blind placebo-controlled clinical trial. *Eur J Clin Nutr.* 1994; 48:633-642.
84. Odeh RM, Cornish LA. Natural antioxidants for the prevention of atherosclerosis. *Pharmacotherapy* 1995;15:648-59. Diplock AT. Antioxidant nutrients and disease prevention: an overview. *Am J Clin Nutr.* 1991;53(1 suppl):189S-193S.
85. Packard CJ, Demant T, Stewart JP, *et al.* Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. *J Lipid Res.* 2000; 41: 305-18.
86. Packer L. The role of anti-oxidative treatment in diabetes mellitus. *Diabetologia.* 1993; 36: 1212-13.
87. Palanduz S, Ademoglu E, Gokkusu C, Tamer S. Plasma antioxidants and type 2 diabetes mellitus. *Res Commun Mol Pathol Pharmacol.* 2001; 109: 309-18.

88. Palinski W, Rosenfeld ME, Yl-Herttuala S, *et al.* Low density lipoprotein undergoes oxidative modification in vivo. *Proc Natl Acad Sci* . 1989; 86: 1372-6.
89. Pan MH, Huang TM, Lin JK. Biotransformation of curcumin through reduction and glucuronidation in mice. *Drug Metab Disp*. 1999; 27: 486-94.
90. Pittman RC, Carew TE, Attie AD, Witztum JL, Watanabe Y, Steinberg D. Receptor-dependent and receptor-independent degradation of low density lipoprotein in normal rabbits and in receptor-deficient mutant rabbits. *J Biol Chem*. 1982; 257: 7994-8000.
91. Puhl H, Waeg G, Esterbauer H. Methods to determine oxidation of low-density lipoproteins. *Methods Enzymol*. 1994; 233: 425-41.
92. Quinones-Galvan A, Sironi AM, Baldi S, *et al.* Evidence that acute insulin administration enhances LDL cholesterol susceptibility to oxidation in healthy humans. *Arterioscler Thromb Vasc Biol*. 1999; 19: 2928-32.
93. Ramirez-Tortosa MC, Mesa MD, Aguilera MC, *et al.* Oral administration of a turmeric extract inhibits LDL oxidation and has hypocholesterolemic effects in rabbits with experimental atherosclerosis. *Atherosclerosis*. 1999; 147: 371-8.
94. Ravandi A, Kuksis A, and Shaikh NA. Glycated Phosphatidylethanolamine Promotes Macrophage Uptake of Low Density Lipoprotein and Accumulation of Cholesteryl Esters and Triacylglycerols. *J Biol Chem*. 1999; 274: 16494-500.
95. Reaven PD, Parthasarathy S, Beltz WF, Witztum JL. Effect of probucol dosage on plasma lipid and lipoprotein levels and on protection of low density lipoprotein against in vitro oxidation in humans. *Arterioscler Thromb*. 1992; 12: 318-24.
96. Reaven PD, Parthasarathy S, Grasse BJ, Miller E, Steinberg D, Witztum JL. Effects of oleate-rich and linoleate-rich diets on the susceptibility of low density lipoprotein to oxidative modification in mildly hypercholesterolemic subjects. *J Clin Invest*. 1993; 91: 668-76.
97. Reddy ACP, Lokesh BR. Studies on spice principles as antioxidants in the inhibition of lipid peroxidation of rat liver microsomes. *Mol Cell Biochem*. 1992; 111: 117-24.
98. Retsky KL, Freeman MW, Frei B. Ascorbic acid oxidation product(s) protect human low density lipoprotein against atherogenic modification: anti- rather than prooxidant activity of vitamin C in the presence of transition metal ions. *J Biol Chem*. 1993; 268: 1304-09.
99. Ross R. The pathogenesis of atherosclerosis. An update. *N Engl J Med*. 1986; 314: 488-500.

100. Sanguinetti SM, Brites FD, Fasulo V, *et al.* HDL oxidability and its protective effect against LDL oxidation in Type 2 diabetic patients. *Diabetes Nutr Metab.* 2001; 14: 27-36.
101. Sato Y, Hotta N, Sakamoto N, Matsuoka S, Ohishi N, Yagi K. Lipid peroxide level in plasma of diabetic patients. *Biochemical Medicine.* 1979; 21: 104-7.
102. Schwartz CJ, Valente AJ, Sprague EA. A modern view of atherogenesis. *Am J Cardiol.* 1993; 71: 9B-14B.
103. Shimonov M, Pinchuk I, Bor A, *et al.* Susceptibility of serum lipids to copper-induced peroxidation correlates with the level of high density lipoprotein cholesterol. *Lipids.* 1999; 34: 255-9.
104. Smith C, Mitchinson MJ, Arouma OI, Halliwell B. Stimulation of lipid peroxidation and hydroxyl-radical generation by the contents of human atherosclerotic lesions. *Biochem J.* 1992; 266: 901-5.
105. Sreejayan N, Rao MNA. Curcuminoids as potent inhibitors of lipid peroxidation. *J Pharm Pharmacol.* 1994; 46: 1013-6.
106. Sreejayan N. Free radical scavenging activity of curcuminoids. *Arzneimittelforschung.* 1996; 46: 169-71.
107. Srimal RC, Dhawan BN. Pharmacological and clinical studies on *Curcuma longa*. *Hamard Natl.* 1985; Section 3B(ii): 131-8.
108. Srinivasan KR. Chromatographic study of the curcuminoids in *Curcuma longa*. *J Pharm Pharmacol.* 1953; 5: 448-60.
109. Steinberg D, and Witztum JL. Lipoproteins and atherogenesis. *Current concepts.* 1990; 264: 3047-52.
110. Steinberg D, Parasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. *N Engl J Med.* 1989; 320: 915-24.
111. Steinberg D. Oxidative modification of LDL and atherogenesis. *Circulation.* 1997; 95: 1062-71.
112. Steiner G, Vranic M, Hollenberg CH. Atherosclerosis, the major complication of diabetes in comparison of type I and type II diabetes. New York: *Plenum.* 1985; 277-97.

113. Stender S, Zilbersmit DB. Transfer of plasma lipoprotein components and of plasma proteins into aortas of cholesterol-fed rabbits: molecular size and determinant of plasma lipoprotein influx. *Arteriosclerosis*. 1981; 1: 28-49.
114. Tall AR. An overview of reverse cholesterol transport. *Eur Heart J*. 1998; 19 Suppl A: A31-55.
115. Tall AR. Plasma cholesteryl ester transfer protein. *J Lipid Res*. 1993; 34: 1255-74.
116. Taskinen MR, Kuusi T. Enzymes involved in triglyceride hydrolysis. *Baillieres Clin Endocrinol Metab*. 1987; 1: 639-66.
117. Tikkanen MJ, Schonfeld G. The recognition domain for the low density lipoprotein cellular receptor is expressed once on each lipoprotein particle. *Biochem Biophys Res Commun*. 1985; 126: 773-7.
118. Van Berkel TJ, Fluiter K, van Velzen AG, Vogelesang CJ, Ziere GJ. LDL receptor-independent and -dependent uptake of lipoproteins. *Atherosclerosis*. 1995; 118: 43-50.
119. Vlassara H. Advanced glycation end-products and atherosclerosis. *Ann Med*. 1996; 28: 419-26.
120. Wheeler DC, Chana R, Thomas GJ, Steadman R, Williams JD, Davies M. Low density lipoprotein stimulate the production of hyaluronan by human mesangial cells *in vitro*. *J Am Soc Nephrol* 1994; 5: 823.
121. Witztum JL. The oxidation hypothesis of atherosclerosis. *Lancet*. 1994; 344: 793-5.
122. Wozniak G, Anuszevska EL. Influence of vitamins C and E on cytotoxic activity of adriamycin in chosen cell cultures. *Acta Pol Pharm*. 2002; 59: 31-5.
123. Yla-Hertuala S. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. *J Clin Invest*. 1989; 84: 1086-95.
124. Young NL, Lopez DR, McNamara DJ, and Benavides G. Evaluation of the contribution of dietary cholesterol to hypercholesterolemia in diabetic rats and of sitosterol as a recovery standard for cholesterol absorption. *J Lipid Res*. 1985; 26: 62-9.
125. Zhang W, Wojta J, Binder BR. Effect of notoginsenoside R1 on the synthesis of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in cultured human umbilical vein endothelial cells. *Arterioscler Thromb*. 1994; 14: 1040-6.